Last reviewed · How we verify
Dendritic Cell Fusion Vaccine
Dendritic Cell Fusion Vaccine is a Biologic drug developed by Beth Israel Deaconess Medical Center. It is currently in Phase 2 development.
At a glance
| Generic name | Dendritic Cell Fusion Vaccine |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (PHASE1, PHASE2)
- DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission (PHASE2)
- DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM (PHASE1)
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (PHASE1)
- The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma (PHASE1, PHASE2)
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (PHASE1)
- Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC (PHASE2)
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dendritic Cell Fusion Vaccine CI brief — competitive landscape report
- Dendritic Cell Fusion Vaccine updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI
Frequently asked questions about Dendritic Cell Fusion Vaccine
What is Dendritic Cell Fusion Vaccine?
Dendritic Cell Fusion Vaccine is a Biologic drug developed by Beth Israel Deaconess Medical Center.
Who makes Dendritic Cell Fusion Vaccine?
Dendritic Cell Fusion Vaccine is developed by Beth Israel Deaconess Medical Center (see full Beth Israel Deaconess Medical Center pipeline at /company/beth-israel-deaconess-medical-center).
What development phase is Dendritic Cell Fusion Vaccine in?
Dendritic Cell Fusion Vaccine is in Phase 2.